PPD, Evidera join NEWDIGS Initiative at MIT as a Strategic Partner
Collaboration to drive innovation across health care ecosystem
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180522005814/en/
PPD is the first contract research organization to join NEWDIGS, expanding the group’s already large and diverse list of global collaborators, which includes biopharmaceutical manufacturers, care providers, regulators, payers, health authorities, health technology assessment bodies, patient advocacy groups and other health care stakeholders. NEWDIGS provides its members an environment, programs and practices for open, non-competitive collaboration so they can develop solutions for systemwide impediments to biomedical innovation and patient care.
“We are excited to be a NEWDIGS partner because it is a results-focused organization active in many of the same areas in which we have expertise,” said
Evidera initially will participate in the new Learning Ecosystems Accelerator for Patient-Centered, Sustainable Innovation (LEAPS) project, in which it will help design and pilot an ecosystem for purpose-driven evidence generation and integration focused on a critical disease area (including both real-world evidence and data from randomized controlled trials). The project aims to create sustainable, commercially viable and scalable tools – including platform trial infrastructure and its extension into community health care settings – to drive more value faster to patients in ways that work for all stakeholders in health care development and delivery.
“We are pleased to welcome PPD and Evidera to the NEWDIGS community of health care innovators,” said
LEAPS work areas will evolve over time, but may include:
- Enhancing evidence planning and production across the drug development life span to fuel sustainable patient-centered innovation
- Applying systems engineering methods and tools to enable seamless, continuous learning and improvement across the innovation value chain (from R&D to care delivery) for a target disease
- Exploring potential applications of transformative technologies and methods, such as blockchain and artificial intelligence/machine learning
For more information on how NEWDIGS and PPD are working together to advance these areas, please contact Evidera.
About PPD
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 47 countries and approximately 20,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health. For more information, visit www.ppdi.com.
About Evidera
Evidera, a PPD business unit, is a leading provider of evidence-based solutions to demonstrate the real-world effectiveness, safety and value of health care products. We help biopharmaceutical, biotechnology and medical device companies generate the evidence needed to optimize the market access and commercial potential of their products. For more information, visit www.evidera.com.
About NEWDIGS
The NEW Drug Development ParadIGmS (NEWDIGS) Initiative at
View source version on businesswire.com: https://www.businesswire.com/news/home/20180522005814/en/
PPD Contacts
Media:
[email protected]
or
Investors:
[email protected]
or
Operations Director
[email protected]
Source: PPD
Employers are Accelerating Adoption of Benefits Technology to Meet the Needs of Tomorrow’s Workplace
The U.S. hospital & nursing homes probiotics market size is expected to reach USD 203.7 million in 2025
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News